Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Depreciation & Amortization (CF) (2016 - 2025)

Avanos Medical (AVNS) has disclosed Depreciation & Amortization (CF) for 13 consecutive years, with $9.9 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 10.81% to $9.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38.9 million through Dec 2025, down 14.51% year-over-year, with the annual reading at $38.9 million for FY2025, 14.51% down from the prior year.
  • Depreciation & Amortization (CF) hit $9.9 million in Q4 2025 for Avanos Medical, up from $9.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $13.4 million in Q4 2022 to a low of $9.4 million in Q3 2025.
  • Historically, Depreciation & Amortization (CF) has averaged $10.8 million across 5 years, with a median of $11.1 million in 2022.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 41.05% in 2022 and later dropped 19.66% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $9.5 million in 2021, then skyrocketed by 41.05% to $13.4 million in 2022, then decreased by 14.18% to $11.5 million in 2023, then dropped by 3.48% to $11.1 million in 2024, then fell by 10.81% to $9.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for AVNS at $9.9 million in Q4 2025, $9.4 million in Q3 2025, and $10.0 million in Q2 2025.